Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 13, 2023 07:30 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update

Highlights progress, recent developments and upcoming key milestonesCompany continues to build growing body of data across pipeline, advancing towards first in human studiesStrong financial position...
March 16, 2023 08:05 ET | Source: Aeterna Zentaris Inc

Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)

Pharmanovia to acquire license to GHRYVELIN™ from Aeterna Zentaris’ existing licensee, Consilient Health, effective immediately TORONTO, ONTARIO, March 16, 2023 (GLOBE NEWSWIRE) -- Aeterna...
January 10, 2023 08:05 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event

Live video webcast on Thursday, January 19th at 3:00 PM ET TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a...
November 03, 2022 08:05 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris Reports Third Quarter 2022 Financial Results

– Company ended the quarter with $53.8 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Nov. 03, 2022 ...
May 05, 2021 08:05 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris Reports First Quarter 2021 Financial Results and Provides Pipeline Program Updates

– Q1 2021 marked by solid operational execution with expansion and diversification of pipeline, intellectual property and portfolio of assets – Pivotal Phase 3 DETECT (Study P02)...
February 16, 2021 17:19 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris Announces $10.0 Million Bought Deal Offering of Common Shares

CHARLESTON, S.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...